Ipsen has restructured its ongoing partnership with Inspiration Biopharmaceuticals for the development and commercialisation of recombinant haemophilia products. Under the terms of the renegotiated agreement, Ipsen recovers commercial rights to OBI-1, a recombinant porcine factor VIII, and gains commercial rights to IB1001, a recombinant factor IX, in Europe, Russia and the CIS, specific Asia-Pacific territories and certain countries in North Africa. Inspiration remains responsible for the global development of the two late-stage drug candidates and could earn US$215 M in upfront, milestone payments and investments.